Human Early Life Exposome (HELIX) study: a European population-based exposome cohort

Léa Maître(Universitat Pompeu Fabra), Jeroen de Bont(Universitat Pompeu Fabra), Maribel Casas(Universitat Pompeu Fabra), Oliver Robinson(Universitat Pompeu Fabra), Gunn Marit Aasvang(Norwegian Institute of Public Health), Lydiane Agier(Centre National de la Recherche Scientifique), Sandra Andrušaitytė(Vytautas Magnus University), Ferrán Ballester(Universitat Jaume I), Xavier Basagaña(Universitat Pompeu Fabra), Eva Borràs(Universitat Pompeu Fabra), Céline Brochot(Institut national de l'environnement industriel et des risques), Mariona Bustamante(Universitat Pompeu Fabra), Ángel Carracedo(Universidade de Santiago de Compostela), Montserrat de Castro(Universitat Pompeu Fabra), Audrius Dėdelė(Vytautas Magnus University), David Donaire-González(Universitat Pompeu Fabra), Xavier Estivill(Hospital Universitario Dexeus), Jorunn Evandt(Norwegian Institute of Public Health), Serena Fossati(Universitat Pompeu Fabra), Lise Giorgis-Allemand(Centre National de la Recherche Scientifique), Juan R. González(Universitat Pompeu Fabra), Berit Granum(Norwegian Institute of Public Health), Regina Gražulevičienė(Vytautas Magnus University), Kristine B. Gützkow(Norwegian Institute of Public Health), Line Småstuen Haug(Norwegian Institute of Public Health), Carles Hernandéz-Ferrer(Universitat Pompeu Fabra), Barbara Heude(Inserm), Jesús Ibarluzea(University of the Basque Country), Jordi Júlvez(Universitat Pompeu Fabra), Marianna Karachaliou(University of Crete), Hector C. Keun(Imperial College London), Norun Hjertager Krog(Norwegian Institute of Public Health), Chung‐Ho E. Lau(Imperial College London), Vasiliki Leventakou(University of Crete), Sarah Lyon-Caen(Centre National de la Recherche Scientifique), Cyntia Manzano(Universitat Pompeu Fabra), Dan Mason(Bradford Teaching Hospitals NHS Foundation Trust), Rosemary McEachan(Bradford Teaching Hospitals NHS Foundation Trust), Helle Margrete Meltzer(Norwegian Institute of Public Health), Inga Petravičienė(Vytautas Magnus University), Joane Quentin(Centre National de la Recherche Scientifique), Theano Roumeliotaki(University of Crete), Eduard Sabidó(Universitat Pompeu Fabra), Pierre‐Jean Saulnier(Inserm), Alexandros Siskos(Imperial College London), Valérie Siroux(Centre National de la Recherche Scientifique), Jordi Sunyer(Universitat Pompeu Fabra), Ibón Tamayo(Harvard University), José Urquiza(Universitat Pompeu Fabra), Marina Vafeiadi(University of Crete), Diana van Gent(Universitat Pompeu Fabra), Marta Vives-Usano(Universitat Pompeu Fabra), Dagmar Waiblinger(Bradford Teaching Hospitals NHS Foundation Trust), Charline Warembourg(Universitat Pompeu Fabra), Leda Chatzi(University of Southern California), Muireann Coen(Imperial College London), Peter van den Hazel(Veiligheids- en Gezondheidsregio Gelderland-Midden), Mark Nieuwenhuijsen(Universitat Pompeu Fabra), Rémy Slama(Centre National de la Recherche Scientifique), Cathrine Thomsen(Norwegian Institute of Public Health), John Wright(Bradford Teaching Hospitals NHS Foundation Trust), Martine Vrijheid(Universitat Pompeu Fabra)
BMJ Open
September 1, 2018
Cited by 273Open Access
Full Text

Abstract

PURPOSE: Essential to exposome research is the collection of data on many environmental exposures from different domains in the same subjects. The aim of the Human Early Life Exposome (HELIX) study was to measure and describe multiple environmental exposures during early life (pregnancy and childhood) in a prospective cohort and associate these exposures with molecular omics signatures and child health outcomes. Here, we describe recruitment, measurements available and baseline data of the HELIX study populations. PARTICIPANTS: The HELIX study represents a collaborative project across six established and ongoing longitudinal population-based birth cohort studies in six European countries (France, Greece, Lithuania, Norway, Spain and the UK). HELIX used a multilevel study design with the entire study population totalling 31 472 mother-child pairs, recruited during pregnancy, in the six existing cohorts (first level); a subcohort of 1301 mother-child pairs where biomarkers, omics signatures and child health outcomes were measured at age 6-11 years (second level) and repeat-sampling panel studies with around 150 children and 150 pregnant women aimed at collecting personal exposure data (third level). FINDINGS TO DATE: Cohort data include urban environment, hazardous substances and lifestyle-related exposures for women during pregnancy and their offspring from birth until 6-11 years. Common, standardised protocols were used to collect biological samples, measure exposure biomarkers and omics signatures and assess child health across the six cohorts. Baseline data of the cohort show substantial variation in health outcomes and determinants between the six countries, for example, in family affluence levels, tobacco smoking, physical activity, dietary habits and prevalence of childhood obesity, asthma, allergies and attention deficit hyperactivity disorder. FUTURE PLANS: HELIX study results will inform on the early life exposome and its association with molecular omics signatures and child health outcomes. Cohort data are accessible for future research involving researchers external to the project.


Related Papers

No related papers found

Powered by citation graph analysis